Download presentation
Presentation is loading. Please wait.
Published byJonas Cunningham Modified over 8 years ago
1
Apolipoproteins as markers and managers of coronary risk by D.C. Chan, and G.F. Watts QJM Volume 99(5):277-287 April 24, 2006 © The Author 2006. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
2
Schematic summary of the endogenous pathways of the atherogenic and anti-atherogenic lipoproteins. D.C. Chan, and G.F. Watts QJM 2006;99:277-287 © The Author 2006. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
3
Low-density lipoprotein particle number, size and composition in different metabolic states: (A) familial hypercholesterolaemia; (B) normolipidaemia; and (C) metabolic syndrome. D.C. Chan, and G.F. Watts QJM 2006;99:277-287 © The Author 2006. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
4
Effect of atorvastatin on LDL cholesterol (A) and apoB levels (B) in the ACCESS study (reference 40). D.C. Chan, and G.F. Watts QJM 2006;99:277-287 © The Author 2006. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.